CLINICAL P

Anotacoes

CLINICAL PHARMACOLOGY 3 Suwicha Limvorasak, PharmD, and Paul S. Wissel, MD, FASCO RECENT UPDATES u The US Food and Drug Administration (FDA) approved 55 novel oncologic drugs in 2023, the second highest count in the past 30 years.1 Key updates on recent approval include the following: ! A next-generation immunotherapy beyond checkpoint inhibitor has been recently approved, in April 2024. Nogapendekin alfa inbakicept is a first-in-class IL-15 agonist immunotherapy approved for treatment of non–muscle-invasive bladder cancer. It activates and drives proliferation of natural killer (NK) and CD81 killer T cells to attack cancer cells, plus CD41 helper T cells, improving durability of response.2 ! Menin inhibitors represent a new and important class of drugs that have shown promising results in histone-lysine N-methyltransferase 2A (KMT2A)-rearranged (KMT2A) and in NPM1-mutated acute leukemia. Revumenib is the first in class and recently gained FDA approval, in November 2024, for treatment of relapsed or refractory acute myeloid leukemia with a KMT2A translocation. It inhibits menin-KMT2A binding, preventing the formation of the specific fusion complex on chromatin, leading to the downr...